Status of work in August
AOTMiT begins work on the Ministry of Health’s orders in August:
- Imfinzi (durvalumab) in the treatment of patients with hepatocellular carcinoma or bile duct cancer
- Tevimbra (tislelizumab) in the treatment of patients with lung cancer and pleural mesothelioma
- Givlaari (givosiran) for the treatment of patients with acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older
The listed order is available on the AOTMiT Public Information Bulletin.